Get the Stockscreener App
0.6549
5.21%
+0.0328
Eyenovia Inc stock is currently priced at $0.6549, with a 24-hour trading volume of 93,718.
It has seen a +5.21% increased in the last 24 hours and a -20.79% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.6446 pivot point. If it approaches the $0.6792 resistance level, significant changes may occur.
Previous Close:
$0.6221
Open:
$0.62
24h Volume:
93,718
Market Cap:
$33.51M
Revenue:
-
Net Income/Loss:
$-27.26M
P/E Ratio:
-0.9491
EPS:
-0.69
Net Cash Flow:
$-27.81M
1W Performance:
-13.88%
1M Performance:
-20.79%
6M Performance:
-63.02%
1Y Performance:
-76.71%
1D Range:
$0.62
$0.67
52W Range:
$0.501
$2.81
Eyenovia Inc Stock (EYEN) Company Profile
Name
Eyenovia Inc
Sector
Industry
Phone
917-289-1117
Address
501 Fifth Avenue, Suite 1404, New York, NY
Eyenovia Inc Stock (EYEN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-01-21 | Initiated | Northland Capital | Outperform |
| Feb-03-20 | Downgrade | Oppenheimer | Outperform → Perform |
Eyenovia Inc Stock (EYEN) Latest News
Eyenovia Inc [EYEN] Shares Fall -5.71 % on Wednesday – Knox Daily - Knox Daily
Knox Daily
Eyenovia Inc (EYEN) is an excellent investment, but the stock is overvalued/undervalued right now – US Post News - US Post News
US Post News
You might want to take a look at Eyenovia Inc (EYEN) now – Sete News - SETE News
SETE News
Eyenovia Announces Corporate Strategy Update Presentation - TipRanks.com - TipRanks
TipRanks
Eyenovia Inc (EYEN) Stock: 52-Week Performance Insights and Trading Volume - The InvestChronicle
The InvestChronicle
US FDA approves Eyenovia's pupil-dilating spray - Yahoo Canada Shine On
Yahoo Canada Shine On
Eyenovia Inc Stock (EYEN) Financials Data
Eyenovia Inc (EYEN) Net Income 2024
EYEN net income (TTM) was -$27.26 million for the quarter ending December 31, 2023, a +2.68% increase year-over-year.
Eyenovia Inc (EYEN) Cash Flow 2024
EYEN recorded a free cash flow (TTM) of -$27.81 million for the quarter ending December 31, 2023, a -7.03% decrease year-over-year.
Eyenovia Inc (EYEN) Earnings per Share 2024
EYEN earnings per share (TTM) was -$0.65 for the quarter ending December 31, 2023, a +22.62% growth year-over-year.
Eyenovia Inc Stock (EYEN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Grant Stuart M. | 10% Owner |
Mar 19 '24 |
Buy |
1.23 |
50,000 |
61,500 |
5,330,715 |
| Grant Stuart M. | 10% Owner |
Mar 08 '24 |
Buy |
1.58 |
10,717 |
16,911 |
5,280,715 |
| Rowe Michael M | Chief Executive Officer |
Dec 04 '23 |
Buy |
1.36 |
4,890 |
6,650 |
32,927 |
| Strahlman Ellen R | Director |
Sep 29 '23 |
Buy |
1.68 |
4,820 |
8,098 |
75,113 |
| Rowe Michael M | Chief Executive Officer |
Sep 19 '23 |
Buy |
1.66 |
1,400 |
2,324 |
28,037 |
| Rowe Michael M | Chief Executive Officer |
Sep 15 '23 |
Buy |
1.75 |
1,137 |
1,990 |
26,637 |
| Grant Stuart M. | 10% Owner |
Aug 17 '23 |
Buy |
1.87 |
30,000 |
56,100 |
5,269,998 |
| Grant Stuart M. | 10% Owner |
Aug 16 '23 |
Buy |
1.91 |
45,000 |
85,815 |
5,239,998 |
About Eyenovia Inc
Eyenovia, Inc., a clinical stage biopharmaceutical company, engages in developing a pipeline of ophthalmology products in the United States. It is developing MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma; MicroStat, which is in Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of dry eye; and MicroPine for the treatment of myopia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was founded in 2014 and is based in New York, New York.
0.57%
1.14%
Cap:
|
Volume (24h):